Naxitamab
14th April 2019
Unassigned
New Medicines
High-risk neuroblastoma in children (aged ≥1 year) and adults
Information
New molecular entity
Y-mAbs Therapeutics
Y-mAbs Therapeutics
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Humanised anti-GD2 3F8 monoclonal antibody (IgG1). GD2 is a disialoganglioside expressed on almost all of neuroblastoma cancer cells regardless of disease stage and in almost all osteosarcomas, but a highly restricted expression on normal tissue.
Fewer than 100 children are diagnosed with neuroblastoma each year in the UK. However, neuroblastomas are the most common extracranial solid tumour of childhood [1]. ·
High-risk neuroblastoma in children (aged ≥1 year) and adults
Intravenous infusion